Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|April 2, 2021
- Pharmaceutical Technology-04-02-2021
- Volume 45
- Issue 4
Miniature Smart Sensors
SICK introduced the SICK W4F line of miniature smart sensors designed to reach next-generation detection performance while including new optical technologies to solve typical pharmaceutical sensing challenges.
SICK introduced the SICK W4F line of miniature smart sensors designed to reach next-generation detection performance while including new optical technologies to solve typical pharmaceutical sensing challenges. Comprised of eight different sensor types, the sensors each feature a 16-mm x 40-mm x 12-mm housing, BluePilot push-turn pinpoint alignment, on-sensor status display, and machine integration options for multiple application regardless of available mounting space.
The sensors are divided into two ranges, Optical Experts and Optical Standards. New additions within the Optical Experts group include the SICK W4F MultiSwitch for detecting objects while upright or on their sides; the W4F Foreground Suppression for detecting flat products and blister packs; the W4F V-Optic for detecting mirror-reflective or completely transparent products; and the SICK W4F DoubleLine to detect components with uneven surfaces, recesses, holes, perforations, grids, or grooves. The Optical Standards range features the new W4F Narrow-beam sensor for detection of jet-black objects with a remission of less than 1%.
Articles in this issue
over 5 years ago
Advanced Manufacturing Technologies Shift Outside the Boxover 5 years ago
Reshoring and Expanding API Manufacturing Capabilitiesover 5 years ago
Balancing the Art and Science of Topical Drug Formulationover 5 years ago
Focusing on Accelerated Formulation Strategiesover 5 years ago
Understanding the Impact of Annex 1 on Isolator Operationover 5 years ago
Blocking the Threat of Counterfeit Medicinesover 5 years ago
Limitations and Advances in Dissolution TestingRelated to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
5